Overview

A Study of LY3475766 in Healthy Participants

Status:
Completed
Trial end date:
2021-03-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of LY3475766 when given to participants with high levels of blood fat called triglycerides. It will also investigate how the body processes the study drug and the effect of the study drug on the body. Information about any side effects will be documented. This study will last up to 16 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company